Ginkgo Bioworks/$DNA
Ginkgo Bioworks shares are trading higher after the company launched a cost-effective ADME profiling service using lab automation, aiming to compete with international vendors.
17 minutes ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Ticker
$DNA
Sector
Primary listing
NYSE
Industry
Chemicals
Headquarters
Employees
834
ISIN
US37611X2099
Website
Ginkgo Bioworks Metrics
BasicAdvanced
$571M
-
-$8.92
1.29
-
Price and volume
Market cap
$571M
Beta
1.29
52-week high
$16.85
52-week low
$5.00
Average daily volume
1.5M
Financial strength
Current ratio
4.881
Quick ratio
4.704
Long term debt to equity
67.121
Total debt to equity
67.121
Interest coverage (TTM)
-4,156.53%
Profitability
EBITDA (TTM)
-325.197
Gross margin (TTM)
80.04%
Net profit margin (TTM)
-198.84%
Operating margin (TTM)
-164.57%
Effective tax rate (TTM)
0.09%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-16.99%
Return on equity (TTM)
-57.76%
Valuation
Price to revenue (TTM)
2.176
Price to book
0.82
Price to tangible book (TTM)
0.92
Price to free cash flow (TTM)
-1.496
Free cash flow yield (TTM)
-66.84%
Free cash flow per share (TTM)
-652.41%
Growth
Revenue change (TTM)
13.76%
Earnings per share change (TTM)
-48.63%
3-year revenue growth (CAGR)
-18.47%
3-year earnings per share growth (CAGR)
-48.93%
Bulls say / Bears say
Ginkgo Bioworks has expanded its partnerships with major pharmaceutical companies, including Merck and Boehringer Ingelheim, to enhance biologics manufacturing and develop novel therapies, potentially leading to increased revenue streams. (prnewswire.com, prnewswire.com)
The company reported a 27% year-over-year increase in total revenue for Q1 2025, indicating positive financial momentum. (biospace.com)
Ginkgo's strategic acquisitions, such as Patch Biosciences and Reverie Labs, are expected to enhance its capabilities in AI and biopharma, positioning the company for future growth. (prnewswire.com)
Despite revenue growth, Ginkgo Bioworks reported a net loss of $91 million in Q1 2025, highlighting ongoing profitability challenges. (biospace.com)
The company's operating margin remains significantly negative at -236.3%, driven by high R&D and SG&A expenses, indicating financial inefficiencies. (marketbeat.com)
Ginkgo's cash reserves have declined from $1.32 billion in 2022 to $312.4 million in Q1 2025, raising concerns about its financial sustainability. (aipha.io)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ginkgo Bioworks stock?
Ginkgo Bioworks (DNA) has a market cap of $571M as of July 18, 2025.
What is the P/E ratio for Ginkgo Bioworks stock?
The price to earnings (P/E) ratio for Ginkgo Bioworks (DNA) stock is 0 as of July 18, 2025.
Does Ginkgo Bioworks stock pay dividends?
No, Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Ginkgo Bioworks dividend payment date?
Ginkgo Bioworks (DNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Ginkgo Bioworks?
Ginkgo Bioworks (DNA) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.